Page 31 - Read Online

Ballestri et al. Metab Target Organ Damage 2023;3:1 https://dx.doi.org/10.20517/mtod.2022.23 Page 19 of 22

patients with biopsy-proven nonalcoholic steatohepatitis. J Am Med Assoc 2021;326:2031-42. DOI
26. Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive review and updates on holistic approach towards non-alcoholic fatty
liver disease management with cardiovascular disease. Curr Atheroscler Rep 2022;24:515-32. DOI PubMed
27. Yang YM, Wang Z, Matsuda M, Seki E. Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic
steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model. Arch Pharm Res 2021;44:230-40. DOI
PubMed PMC
28. Pritchard MT, McCracken JM. Identifying novel targets for treatment of liver fibrosis: what can we learn from injured tissues which
heal without a scar? Curr Drug Targets 2015;16:1332-46]. DOI PubMed PMC
29. Andreichenko IN, Tsitrina AA, Fokin AV, et al. 4-methylumbelliferone prevents liver fibrosis by affecting hyaluronan deposition,
fstl1 expression and cell localization. Int J Mol Sci 2019;20:6301. DOI PubMed PMC
30. Weiz G, Molejon MI, Malvicini M, et al. Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma.
Liver Int 2022;42:444-57. DOI PubMed
31. Diagnosis of fibrosis and cirrhosis. Liver biopsy is not always necessary. Prescrire Int 2010;19:38. PubMed
32. Lai M, Afdhal NH. Liver fibrosis determination. Gastroenterol Clin North Am 2019;48:281-9. DOI PubMed
33. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based
biomarkers. J Hepatol 2018;68:305-15. DOI PubMed
34. Boyle M, Tiniakos D, Schattenberg JM, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver
disease. JHEP Rep 2019;1:188-98. DOI PubMed PMC
35. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol
2022;76:1362-78. DOI PubMed
36. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis relationship to cirrhosis.
Gastroenterology 1988;95:734-9. DOI PubMed
37. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive
model. Hepatology 2002;36:986-92. DOI
38. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients
with chronic hepatitis C. Hepatology 2003;38:518-26. DOI PubMed
39. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical
scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7. DOI PubMed
40. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with
HIV/HCV coinfection. Hepatology 2006;43:1317-25. DOI PubMed
41. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with
NAFLD. Hepatology 2007;45:846-54. DOI PubMed
42. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD
fibrosis. Am J Gastroenterol 2017;112:740-51. DOI PubMed PMC
43. Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver
fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut 2016;65:1369-76. DOI
44. Ampuero J, Pais R, Aller R, et al; HEPAmet Registry. Development and validation of hepamet fibrosis scoring system-a simple,
noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol
2020;18:216-225.e5. DOI PubMed
45. Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with
higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics (Basel) 2021;11:98. DOI
PubMed PMC
46. Brandman D, Boyle M, McPherson S, et al. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver
disease (NAFLD). Aliment Pharmacol Ther 2022;55:1441-51. DOI
47. Sun W, Cui H, Li N, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in
adult patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol Res 2016;46:862-70. DOI PubMed
48. Boursier J, Canivet CM, Costentin C, et al. Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with
resulting clinical implications. Clin Gastroenterol Hepatol ;2022:S1542-3565(22)00248. DOI
49. Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the
noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015;35:1566-73.
DOI PubMed
50. Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score
combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty
liver disease study. Eur J Gastroenterol Hepatol 2020;32:642-9. DOI PubMed
51. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-
alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet
Gastroenterol Hepatol 2020;5:362-73. DOI PubMed PMC
52. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in
assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717-30. DOI PubMed